Skip to content

Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital

Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07119905
Enrollment
80
Registered
2025-08-13
Start date
2026-06-01
Completion date
2027-02-01
Last updated
2025-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Open Angle Glaucoma (POAG)

Keywords

Primary Open Angle Glaucoma, POAG, Gene Polymorphism, MMP-9, Matrix Metalloproteinase-9 Gene Polymorphism

Brief summary

The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to

Detailed description

Glaucoma is the second most common cause of blindness worldwide. Glaucoma is a progressive optic neuropathy, characterized by a specific loss of retinal nerve fibres and ganglion cells, gradual decrease of the visual field, and vertical elongation of optic disc cupping. Glaucoma causes a slow loss of vision in the centre of the field of view as well as in the periphery. This results in delays in the diagnosis and treatment, and it is likely that the glaucoma may not be diagnosed until the disease has progressed to a moderate or severe level, at which point significant vision loss will have already taken place POAG is the most common type of glaucoma that is characterized by specific glaucomatous retinal, optic nerve, and clinical findings without a clear secondary cause. POAG is a progressive optic neuropathy characterized by loss of ganglion cells and deterioration of the visual field in eyes with gonioscopically open angles, either with or without increased intraocular pressure (IOP). Matrix Metalloproteinase-9 gene Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis. The MMP genes were suggested to play an important role in the development of various glaucoma types, MMPs are important regulators of the aqueous humor outflow from the eye anterior chamber and therefore significantly affect intraocular pressure. Patients with diagnosed POAG have an altered MMPs level in the aqueous humor. Several studies have been conducted to analyze polymorphic variants of the MMP for their possible contribution to POAG, Several loci of the MMP genes (rs3918242, rs3918249, rs17576 matrix metalloproteinase-9 were associated with POAG.

Interventions

GENETICgenotyping assay by polymerase chain reaction

Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube. Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men and women older than 30 years * Primary open angle glaucoma as evidenced from characteristic visual field loss and optic disc cupping (POAG group) * Healthy subjects matched by age, sex and ethnicity to the POAG patients group (control group)

Exclusion criteria

* Exfoliation glaucoma, pigmentary glaucoma * History of acute angle closure

Design outcomes

Primary

MeasureTime frameDescription
Matrix metalloproteinase-9 gene polymorphism14 monthsMatrix metalloproteinase-9 gene polymorphism by polymerase chain reaction

Countries

Egypt

Contacts

Primary ContactThomas Talaat Nageh, Demonstrator
thomas.talaat@med.sohag.edu.eg20 1276890796

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026